Southern Therapy and Advanced Research, LLC | Jackson, MS

Research site

(Unclaimed)

Location

971 Lakeland Drive, Suite 1159, Jackson, Mississippi, United States of America

Site insights

Top conditions

Top treatments

Obeticholic Acid

MGL-3196

Cilofexor

Resmetirom

RBV

Semaglutide

K-877-ER

UDCA

OCA

DUR-928

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 26 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Procedure: Liver Biopsy

Drug: MGL-3196

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling

Crohn's Disease

Drug: Placebo

Drug: Etrasimod

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

Primary Sclerosing Cholangitis

Drug: Volixibat

Drug: Placebo

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Enrolling

Hepatic Impairment

Compensated Cirrhosis

Drug: Seladelpar 10 mg

Drug: Seladelpar 10 mg or less

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: Cilofexor (CILO)/Firsocostat (FIR)

Drug: PTM SEMA

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Enrolling

NASH

Drug: K-877-ER

Drug: Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms